Quant Before Qual: A Novel Approach to Explore a Provocative Topic in Physician Research

Presented by Olson Research Group

Significance & Prevalence of Oncology Marketing Research

The US healthcare system is expected to spend more than $150B treating cancer by the year 2020.  Compounding this, of the 20 orphan drugs expected to reach blockbuster status by 2018 (+$1B in sales), 13 are oncologic agents.  It is not surprising that the increased number and cost of new oncology therapies has translated into a greater prevalence of marketing research conducted across the broad spectrum of oncology therapies in the past few years.  At Olson Research, we see this evidenced in the sheer number of projects we have undertaken in this therapy area: in the last 18 months alone we have fielded over 300 research studies in oncology.   A recent study we conducted in oncology was designed to uncover oncologists’ perceptions to a new incentive program introduced by health insurer WellPoint, Inc.

Oncology News Event: WellPoint Introduces Incentive Program to Curtail Costs

The last several years have signaled a shift in how payer organizations are attempting to control the escalating costs associated with treating cancer.  A significant rise in both the number and cost of targeted therapies has led payers to initiate programs that encourage oncologists to adhere to standardized treatment guidelines. The trend over the past several years has been to incent oncologists who comply with the treatment protocols established by payers for various cancers. 

In July of 2014, WellPoint, the number two insurer in the United States, began offering oncologists a monetary incentive for each patient who receives treatment for breast, colorectal, and lung cancer, as specified by one of the insurer's recommended regimens.  Oncologists receive a one-time $350 payment at the onset of treatment planning and care coordination. The practice will also receive $350 per month per patient while the patient is active in therapy and on one of the recommended pathways.  This approach by payers to more greatly influence oncologists prescribing choices by incentivizing physicians to choose certain treatment approaches has the potential to be a very polarizing and provocative subject in the oncology community.

Research Question: What Is Oncologists’ Reaction to WellPoint’s Program?

How will WellPoint’s incentive program affect physicians’ and patients’ desire for personalized treatment approaches? How, if at all, will WellPoint’s standardized treatment pathways integrate new, innovative advances in medicine?  WellPoint’s program raises a multitude of issues, including the question of who should be determining treatment:  payers or physicians?

Research Methodology

We first had to determine the best methodology to evaluate perceptions of such a highly provocative issue.  To start, we wanted to measure awareness and understanding among oncologists of the WellPoint Program, and to gauge their reaction upon reviewing primary source information on the program and its intentions.   For this, we needed quantitative measurement.  We elected to field an 8-10-minute online quantitative survey with US oncologists to measure awareness of the program, and gather opinions on how the program might affect their practice and prescribing habits.  From within the survey, physicians were asked to review two primary sources on the WellPoint Program: the WellPoint press release announcing the implementation of the Care Cancer Quality Program, and a Wall Street Journal article  (“Insurers Push to Rein in Spending on Cancer Care”, May 27, 2014) describing the initiative.

Beyond measuring awareness and knowledge, as the topic was explored further, we were aware that the debate surrounding the implications of the WellPoint Program would elicit differing opinions, and we also knew that opinions could be highly personal and rooted in larger issues of physician reimbursement and prescribing autonomy.  We felt that the perceived effects of WellPoint’s program could be most fully explored by generating interaction between oncologists, and we predicted that discussions may become somewhat charged.  Add to this equation the reality of a respondent pool of physicians with the likelihood of dominant personalities and egos, and we felt an online forum discussion would be most appropriate.

At the conclusion of the survey, respondents were asked to consent to a further online discussion forum a few days later to more deeply explore the effect of the WellPoint program on both physician practices and patient care.  The online discussion forum allowed us to capitalize on the richness of the comments from the qualitative elements in our survey.  We were able to take the prevailing arguments uncovered in the first research phase, those both for and against incentive programs such as WellPoint’s, and turn them into discussion topics for the online forum.

Research Findings & Success of Approach

The first phase of the research project was fielded in 2 weeks.  Responses were on-point and thorough; physicians were engaged and interested in the topic.  Oncologists spent an average of 8 minutes on the survey.  The hybrid quant/qual approach of the survey successfully allowed us to measure awareness and understanding of the WellPoint program, while at the same time posing quite a few open-ended questions, allowing us to fully ascertain reactions to the WellPoint program.

Despite the strong opinions voiced by the oncologists who participated in our survey, only 32% indicated that the incentive program might change or alter their behavior.  Many suggested that they are likely to adhere to the treatment pathways recommended in the future. 

Those in favor of the program expressed optimism that the program will dissuade unnecessary excessive treatments and also help to give oncologists some much-needed guidelines or boundaries within which to care for their patients.  Some also opined that personalized medicine can offer patients false hope and that it is better to set expectations based on what medically proven therapies can deliver.

It was evident that the forum approach was the right methodology to use for this population.  Participation was frequent and regular, comments thoughtful, discussions lively, and a few heated debates ensued. (See Figure 2.)  

 

Key Takeaways

Three underlying factors contributed to the success of this research.  First, having a recognized and trusted relationship with your target market facilitates strong participation.  Second, while not always under our control, timely topics or subject matter can assist in fielding success.  Lastly, and perhaps most important, spending time at the project outset to ensure your methodology is most appropriate for the research need can deliver a robust outcome.  We recognize that a quantitative-first, qualitative-second approach is not the customary sequence to marketing research, and that there are sound methodological reasons for pursuing a more traditional trajectory in most cases.  However, the success of this project supports the basic premise that researchers should employ the methodology and tactics that will best deliver results.  Making a sound decision to align the research methodology with your target population, time-frame, and subject matter can ensure successful data collection, a vital element for delivering sound results to clients.



This content was originally published by Olson Research Group, Inc. . Visit their website at www.olsonresearchgroup.com.

Presented by

Featured expert

Olson Research offers qualitative and quantitative market research services with unique access to more than 2.4 million HEALTHCARE DECISION MAKERS.

Why choose Olson Research Group

Access to healthcare

Experienced PMs

In-house programming

Recruiting expertise

Precise targeting

Sign Up for
Updates

Get content that matters, written by top insights industry experts, delivered right to your inbox.

67k+ subscribers